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Abstract
Introduction: Immortalization is a key step in malignant transformation, but immortalization alone is
insufficient for transformation. Human mammary epithelial cell (HMEC) transformation is a complex
process that requires additional genetic changes beyond immortalization and can be accomplished in vitro
by accumulation of genetic changes and expression of H-ras.
Methods: HMEC were immortalized by serial passaging and transduction with the catalytic subunit of the
human telomerase gene (hTERT). The immortalized cells were passaged in vitro and studied by a
combination of G- banding and Spectral Karyotyping (SKY). H-ras transduced, hTERT immortalized cells
were cloned in soft agar and injected into nude mice. Extensive analysis was performed on the tumors that
developed in nude mice, including immunohistochemistry and western blotting.
Results: Immortal HMEC alone were not tumorigenic in γ-irradiated nude mice and could not grow in
soft agar. Late passage hTERT immortalized HMEC from a donor transduced with a retroviral vector
containing the mutant, autoactive, human H-ras61L gene acquired anchorage independent growth
properties and the capacity for tumorigenic growth in vivo. The tumors that developed in the nude mice
were poorly differentiated epithelial carcinomas that continued to overexpress ras. These cells were
resistant to doxorubicin mediated G1/S phase arrest but were sensitive to treatment with a
farnesyltransferase inhibitor.
Conclusion: Some of the cytogenetic changes are similar to what is observed in premalignant and
malignant breast lesions. Despite these changes, late passage immortal HMEC are not tumorigenic and
could only be transformed with overexpression of a mutant H-ras oncogene.
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Introduction
Immortalization is a key step in malignant transforma-
tion, as it allows a cell to indefinitely proliferate while
accumulating genetic abnormalities. Normal human
mammary epithelial cells (HMEC) initially proliferate
robustly in tissue culture before encountering a prolifera-
tion block termed stasis [1,2]. Cells in stasis are less pro-
liferative, appear large and flattened, stain positively for
beta galactosidase, but are non-apoptotic since the cells
are negative by terminal deoxynucleotidyl transferase
mediated dUTP nick end labeling (TUNEL) staining.
HMEC can escape stasis spontaneously, as evidenced by
the fact that a small percentage of HMEC in culture may
pass through stasis and continue to proliferate [1]. The
exact number of passages and percentage of cells that
evade this initial growth arrest are highly dependent upon
individual specimens and culture conditions [1]. It has
been demonstrated that the p16 INK4A tumor suppressor is
inactivated in HMEC escaping stasis [3], primarily by pro-
gressive promoter methylation [4-6]. Cells undergo a sec-
ond mortality stage, termed agonescence [7]. Cells in
agonescence appear small and vacuolated and have criti-
cally shortened telomeres. Activation of telomerase
expression at this stage stabilizes telomere length, allow-
ing cells to pass through agonescence and proliferate
indefinitely.
DNA tumor viruses immortalize cells and provide a useful
model for studying neoplasia. For example, the combined
expression of the catalytic subunit of human telomerase
(hTERT), together with SV40 large T antigen can immor-
talize HMEC. The E6/E7 gene products from "high risk"
human papillomavirus types such as HPV16 can uniquely
immortalize HMEC at any stage without the aid of hTERT
[8].
In vitro models of mammary cell transformation either
require the introduction of viral oncogenes [9-11] or
make use of chemical carcinogens [12], such as benzo
[a]pyrene. Stampfer and Bartley [12] exposed rapidly
growing primary cultures of human mammary epithelial
cells to benzo [a]pyrene for 2–3 days and produced two
immortalized cell lines- 184 A1 and 184 B5. The introduc-
tion of Ras  or  erbB2  into subline 184A1N4 or 184B5
respectively results in production of a malignant pheno-
type [12,13]. Both 184 A1 and 184 B5 have acquired mul-
tiple cytogenetic abnormalities [14]. HBL 100, a cell line
derived from an immortalized mammary cell cultured
from mother's milk, also transforms with the introduction
of a single oncogene [15], but carries an integrated copy of
the SV40 genome and demonstrates a near triploid karyo-
type.
More recently, Elenbaas et al. [9] transformed HMEC by
serial transduction of SV40 large T antigen, SV40 small t
antigen,  hTERT, and a mutant, constitutively active,
human V12G H-ras. Substantial overexpression of H-ras
(12 fold) was required in order to transform the HMEC.
The tumors that were obtained were epithelial, staining
positively for cytokeratin, and negative for the estrogen
and progesterone receptor, consistent with the poorly dif-
ferentiated histology seen on hematoxylin and eosin
staining. Cytogenetic data presented in the paper revealed
frequent increased copy number of the locus containing
the c-Myc oncogene, either through trisomy 8, transloca-
tions involving 8q24, or by creation of isochromosome
for the long arm of chromosome 8 [i(8)(q10)]. Interest-
ingly, cells in the tumor, in which i(8)(q10) was fre-
quently seen, displayed extra copies of chromosomes 5.
One tumor had 22% metaphases with del(12p). One of
the tumors was near tetraploid while the other two were
near diploid (90% and 62% of total cells analyzed).
Toouli et al. [11] transformed HMEC from a single donor
purely through the use of SV40 large T antigen and SV40
small t antigen. Fifty percent of the late passage cell lines
expressing both large T antigen and small t antigen were
tumorigenic. One of the lines showed a 30% take rate,
with a latency of twenty-one days, while the other line
showed a 20% take rate with a latency of sixty-eight days.
No histologic, cytogenetic, or immunohistochemical data
were presented on the tumors. The authors also noted that
none of the hTERT immortalized HMEC lines were tum-
origenic.
In this paper, we describe the cytogenetic characteristics of
a hTERT immortalized human mammary epithelial cell
line, and of a tumorigenic human mammary epithelial
cell line produced through hTERT immortalization, pas-
saging, transduction of H-ras61L, and soft agar cloning.
Materials and methods
Isolation and culture of HMEC
The mammary epithelial cells (HMEC) were all derived
from reduction mammoplasties of individuals with no
known breast pathology, as reconfirmed by histopathol-
ogy of the post-surgical specimens. HMEC were prepared
by the method of Smith et al. [16] and grown at 37°C and
5% CO2 in DFCI-1 media [17]. Cells were allowed to pass
through stasis before infection with the hTERT construct,
as described by Foster et al.[18], Kiyono et al.[3], and
Rothenberg and Nolan [19].
Cell proliferation and staining
HMEC (human normal mammary epithelial cells) and
our tumorigenic cells were seeded in glass 8-well chamber
slides at a concentration of 104 cells per well and treated
with FTI-277 and DMSO at 2.5, 5.0, 10.0, 15.0 and 20.0
μM concentrations for 5 days in duplicate. Cells were
counted using Hemocytometer (blood cell counter) onCancer Cell International 2006, 6:15 http://www.cancerci.com/content/6/1/15
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1st, 2nd and 5th days as well as stained with Phalloidin-TXR
for cytoskeletal staining and DAPI for nuclear staining.
Cytogenetics
Metaphase chromosomes from HMEC were prepared and
G-banded (Wright's stain) using standard cytogenetic
techniques [20]. Briefly, after the cells were incubated
with 0.06 ug/ul of colcemid at 37°C for 2.5 hours, they
were trypsinized with trypsin/EDTA (0.5%/0.1%) and
incubated in 2 ml of a 1:1 (by vol) mixture of 0.8%
sodium citrate and 0.075 M potassium chloride for thirty
minutes at 37 degrees C. This was followed by addition of
1 ml of Carnoy's fixative (3:1 by vol; methanol:acetic
acid) and incubation at room temperature. The fixed cells
were then spun down and resuspended in 1 ml of Car-
noy's fixative. Metaphase chromosomes were prepared for
G-banding and Spectral Karyotyping (SKY). Cells were
analyzed based on clonality criteria and karyotypes were
described by the recommendations of the International
System for Human Cytogenetic Nomenclature (ISCN
2005) [21].
Spectral karyotyping
SKY [22] was used to identify or confirm the G-band kary-
otype assignments. Briefly, SKY is a form of fluorescence
in situ hybridization (FISH) which utilizes a mixture of
"whole chromosome paint" DNA probes to uniquely
label each of the 24 different human chromosomes,
allowing simultaneous visualization and identification of
each chromosome or chromosome derivative. The limit of
resolution of SKY for structural abnormalities is currently
unknown, and the technique will likely not detect subtle,
intra-chromosomal rearrangements, such as small dele-
tions, duplications or inversions. We also cannot rule out
the possibility of mosaicism for numerical or structural
abnormalities given the limited number of cells (usually
five), which are evaluated in this study. Unbanded or de-
stained G-banded metaphase chromosome preparations
were hybridized with the SKY probe mixture and were
analyzed using SKYView imaging software, following the
manufacturer's instructions (Applied Spectral Imaging,
Inc.; Carlsbad, CA). The hybridized metaphase cells were
simultaneously stained with the nuclear stain, DAPI.
When the bright-dark fluorescent bands from chromo-
somes stained with DAPI are reversed by the SKYView
imaging software, a low-resolution G-band-like pattern is
produced that is used to confirm the chromosome iden-
tity and to assign cytogenetic breakpoints on rearranged
chromosomes.
For both G-band and SKY analyses, structural chromo-
some abnormalities and chromosome gains were consid-
ered clonal if the aberration was exhibited in at least two
cells from a culture. Whole chromosome losses were con-
sidered clonal if observed in at least three cells from a cul-
ture, per ISCN convention [21].
Flow cytometry
The protocol as previously described was followed [23].
Cells were lifted from the plate with trypsin/EDTA (0.5%/
0.1%) and fixed overnight in 80% ethanol at 4°C. Cells
were washed with PBS the following day, and this was fol-
lowed by staining in PBS with 10 ug/ml of propidium
iodide for twenty minutes at room temperature.
Transduction of H-ras 61L into HMEC
pCTV3H H-ras61L (a generous gift of Dr. Channing Der)
or pCTV3H (empty control vector) was precipitated and
incubated with Phoenix cells to produce infectious super-
natant [19]. Cells were transduced with either construct by
incubation with 1 ml of infectious supernatant with 4 pg/
ml of polybrene for four hours. Two days later, continu-
ous selection with hygromycin B (20 ug/ml) was initiated
over a several week time span until sustained growth from
a robust population was maintained.
Soft agar assay
Six-well plates were filled with two ml of 0.66% noble
agar in DFCI-1 media as a bottom layer and allowed to
solidify at 4°C overnight. 105 cells were suspended in one
ml of 0.33% noble agar in DFCI-1 media and plated onto
wells. Each well was fed once a week with one ml of
0.33% agar in DFCI-1 media. Wells were scored for colony
growth over the next four weeks. Cell clumps greater than
60 um were scored as colonies.
Nude mice injection and tumor harvesting
Four-week-old female nude mice were γ-irradiated to 300
rads using a linear accelerator and injected subcutane-
ously over the abdomen with 107 cells derived from the
soft agar colony that was regrown in monolayer. The mice
were observed for tumor formation over the following 30
days. Tumors were harvested and cut into two parts. One
part was sent for paraffin embedding, while the other half
was minced and disaggregated with trypsin/EDTA (0.5%/
0.1%) overnight at 4°C, followed by trypsinization for an
additional thirty minutes at 37°C. Single cells were plated
and allowed to grow in DFCI-1 media.
Immunohistochemistry
Immunohistochemistry on paraffin embedded tumor sec-
tions was performed as previously described by Gown and
Vogel [24] at Phenopath Laboratories (Seattle, WA) or the
laboratory of Dr. Peggy Porter (Program in Cancer Biol-
ogy, Fred Hutchinson Cancer Research Center, Seattle,
WA) using 4 um thick sections baked onto positively
charged slides. Immunohistochemical studies were per-
formed on formalin-fixed, paraffin-embedded, tissue sec-
tions using the avidin-biotin-peroxidase complex (ABC)Cancer Cell International 2006, 6:15 http://www.cancerci.com/content/6/1/15
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method. Sections were incubated with a cocktail of two
anti- cytokeratin mouse monoclonal antibodies (AE1 and
AE3, Roche, Indianapolis, IN, 1:200 dilution) that recog-
nizes a wide range of high and low molecular weight
cytokeratins; anti-cytokeratin-7 (OV-TL 12/30, DAKO,
Carpinteria, CA, 1:1000), anti-smooth muscle myosin
heavy chain (SMMS-1, DAKO, 1:30); anti-estrogen recep-
tor (ID5, Zymed, South San Francisco, CA, 1:200); anti-
progesterone receptor (IA6, Lab Vision, 1:50); anti-mam-
moglobin(304-1A5 1;2000, 31A5 1:400, Corixa, Seattle,
WA); anti-cytokeratin 5/6(5/16 B4, Chemicon, Temecula,
CA, 1:1000); anti-cytokeratin 19 (BA 17, DAKO, 1:100),
anti-calponin (Calp, DAKO, 1;1000); anti-cytokeratin 20
(KS 20.8, DAKO, 1:250); anti-cytokeratin 8 (35βH11,
DAKO, 1:50); anti-E-cadherin (HECD-1, Zymed, San
Francisco, CA,1:300); brst-2 (D6, Signet, Dedham, MA,
1:200). After overnight incubation, slides were incubated
with secondary antibody. For polyclonal antibodies raised
in rabbit, biotinylated goat anti-rabbit immunoglobulin
(1:200) was used. For murine monoclonal antibodies, we
used biotinylated goat anti-mouse immunoglobulin
(1:200). Sections were incubated in secondary antibody
for 30 minutes. The peroxidase staining procedure was
done using the ABC Elite kit (Vector laboratories, Burlin-
game, CA). The immunostaining reaction was visualized
using 0.05 % 3,3'- diaminobenzidine in Tris- HCl buffer
containing 0.01 % hydrogen peroxide, pH 7.6.
Western blotting
Total cell protein was extracted from transduced cells by
sonication in We 16 buffer (25 mM Tris HCl- pH 7.5, 125
mM NaCl, 2.5 mM EDTA, 0.05% SDS, 0.5% NP40, 0.5%
DOC, 10% glycerol, 1 mM DTT, 0.5 mg/ml Pefablock,
0.025 mg/ml leupeptin, 0.01 mg/ml pepstatin, 0.01 mg/
ml aprotinin, 0.08 M β glycerophosphate, 0.005 Na3VO4,
0.05 M NaF). Twenty micrograms of protein from each
cell population was electrophoresed and transferred to a
polyvinylidene difluoride membrane (NEN). The mem-
branes were blotted with the following antibodies: H-ras
(LA-069, Quality Biotech, Camden, NJ, 1:10,000); c-Myc
(9E10, BD Biosciences, San Diego, CA, 1:250), Mdm2
(IF2, Oncogene Research Products, Boston, MA, 1:50),
p53 (DO-1, Oncogene Research Products, 1:100), and
actin (c-11, Santa Cruz Biotechnology, Santa Cruz, CA,
1:100). Samples destined for H-ras western blotting were
run on a 15% SDS polyacrylamide gel, while all other
samples were run on 8% polyacrylamide gel. After the
samples were transferred onto the membrane, the mem-
brane was blocked in 10% milk in TBST buffer (10 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20) for
one hour at room temperature or overnight at 4°C. Mem-
branes were then incubated overnight at 4°C with 10 ml
of 5% milk in TBST/0.5% Tween 20 with the primary anti-
body. The following day, membranes were briefly washed
and incubated for one hour with secondary antibody in
5% milk in TBST/0.5% Tween 20 with the appropriate sec-
ondary antibody. Anti- mouse IgG- HRP from Jackson
Immunoresearch Labs (Bar Harbor, ME) was used against
the H-ras (1:35,000), c-Myc (1:10,000), and p53
(1:10,000) primaries. Donkey anti-goat antibody (Santa
Cruz Biotechnology) was used against the polyclonal
actin primary (1:5,000). Blots were developed using the
Renaissance chemiluminescence system (NEN) and
imaged on Kodak Xomat blue film.
Results
hTERT immortalized HMEC from donor # 4 (herein
referred to as HMEC 4-hTERT or RAO-1) at late passage
demonstrated a derivative chromosome 1,
[der(1)t(1;8)(p13;q13)], in addition to two normal cop-
ies of chromosome 1 and two normal copies of chromo-
some 8, in four of five metaphase cells analyzed by SKY.
HMEC 4-hTERT demonstrated trisomy of 1q and 8q due
to the presence of the derivative chromosome, and
showed complete trisomy of chromosomes 5 and 20.
Flow cytometry of HMEC 4-hTERT confirmed a near dip-
loid population. These immortal cell lines analyzed were
not tumorigenic in nude mice and did not demonstrate
anchorage independent growth in soft agar.
Transduction of pCTV3H H-ras61L into hTERT-immortal-
ized late passage (passage 32) HMEC from donor 4 (RAO-
2 cell population) resulted in high levels (at least six fold)
of H-ras expression in these cells as compared to HMEC
(passage 43). At passage 43, 105 cells were cast into soft
agar. H-ras-transduced HMEC demonstrated growth in
soft agar, with at least fifty colonies generated. Of the three
colonies picked at random, the second colony was
expanded in monolayer and injected, at passage 47, into
six nude mice, producing mammary epithelial carcinomas
(RAO-4 cell line). The other two colonies, when injected
into nude mice, produced spindle cell carcinomas (RAO-
3 cell line) and have been described separately [25].
All six mice injected with cells from colony 2 of H-ras61L
transduced HMEC developed tumors subcutaneously at
the site of injection within 21 days. Figures 1a and 1b
illustrate the hematoxylin/eosin staining of a paraffin-
embedded section of the epithelial tumor. The cells are
round and circumscribed. The cells form a sheet with no
differentiated structure and display areas of necrosis, all
consistent with a poorly differentiated carcinoma. The
pan-cytokeratin staining (Figure 1c) is strongly positive,
consistent with the tumor's epithelial origin. The tumor is
cytokeratin 7 positive and negative for cytokeratins 8, 18,
and 20. It is negative for basal/myoepithelial markers
such as cytokeratin 5, smooth muscle myosin heavy
chain, and calponin. The tumor is negative for the estro-
gen receptor and the progesterone receptor. It is negativeCancer Cell International 2006, 6:15 http://www.cancerci.com/content/6/1/15
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for mammoglobin and the brst-2 antigen. The tumor has
also lost E-cadherin expression (data not shown).
Western blot analysis of HMEC from donor 4 reveals
some interesting patterns, shown in Figure 2. H-ras levels
are very low in early passage HMEC. With immortaliza-
tion and subsequent passaging, H-ras levels increase. After
transduction of pCTV3 H-ras61L, H-ras levels increase
substantially and are maintained at a five-fold level of
overexpression through to the tumor. Expression of p53
was at low levels in mortal cells. In late passage immortal
cells, it is expressed at high levels. Ras transduction appar-
ently reduces the level of p53 expression, and a reduced
level of p53 expression is observed in the tumor. c-Myc
takes a very interesting pattern of expression. c-Myc is at
low levels in our post-selection HMEC (lane 1, Figure 2).
It is strongly expressed in RAO-1 (lane 2, Figure 2), but
diminished in RAO-2 cells (lane 3, Figure 2), suggesting
that H-ras61L transduction reduces c-Myc expression.
Finally, c-Myc expression is detected in the soft agar col-
ony (lane 4, Figure 2) that gave rise to the mammary epi-
thelial tumor, and in the RAO-4 tumor cells cultured in
monolayer (lane 5, Figure 2). Mdm 2 levels are stable
throughout this time course.
Single color (DAPI) flow cytometry (Figure 3) of mam-
mary epithelial tumor cells revealed a near diploid popu-
lation with no significant tetraploid population,
confirming the results of cytogenetic analysis. The treat-
ment of H-ras transduced cells with FTI-277, a farnesyl
transferase inhibitor, resulted in a significant change in
cell phenotype observed by a flattened membraneous
morphology in (Figure 4a) and a decrease in cell number
over a period of five days (figure 4b), suggesting that the
cell line is quite sensitive to ras inhibition. No cellular
morphological changes were observed in HMEC at these
concentrations.
Cytogenetic analysis of the tumor revealed at least two
related cell populations: 49, XX, +der(1)t(1;8)(p13;q13),
psu idic(1)(q23),+5,+20 (Figure 5a; Figure 6) and 49, XX,
add(1)(q21),+der(1)t(1;8)(p13;q13),+5,+20 (Figure 6).
Among the cells analyzed, there were chromosome losses,
and analysis could not determine whether they were
clonal or non-clonal.
Spectral Karyotyping was performed on late passage
hTERT immortalized cells (prior to Hras61L transduction)
from donor 4, confirming the presence of many of the
cytogenetic abnormalities seen in the epithelial tumor.
The mainline karyotype in these cells was 49, XX,
+der(1)t(1;8)(p13;q13), +5, +20. Despite the presence of
these extensive cytogenetic abnormalities, these cells were
non-tumorigenic in gamma-irradiated nude mice. Spec-
tral Karyotyping of the epithelial tumor (Figure 5b)
revealed the mainline karyotype to be 49,
XX,+der(1)t(1;8)(p13;q13), psu idic(1)(q23), +5, +20.
Discussion
We hypothesize that the HMEC studied here escaped a tel-
omere length associated crisis through early passage trans-
duction with hTERT resulting in stabilization of telomeres
and transient maintenance of a diploid state, as well as
immortalization. However, the constitutive expression of
the catalytic subunit of telomerase through agonescence
and the disruption of the Rb pathway may carry a price, as
a. Photomicrograph displays a hematoxylin/eosin section (of a section of the mammary epithelial tumor at 40×) Figure 1
a. Photomicrograph displays a hematoxylin/eosin section (of a section of the mammary epithelial tumor at 40×). b. This same 
section at 200×. c. The pan-cytokeratin stain (AE1/AE3) is strongly positive, confirming the epithelial nature of the tumor. Mag-
nification is 200×.Cancer Cell International 2006, 6:15 http://www.cancerci.com/content/6/1/15
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the immortalized cells studied here ultimately developed
specific chromosomal abnormalities (trisomy 5, trisomy
20, gain of 8q, and abnormalities of chromosome 1, some
of which are seen in breast cancer and other neoplasias.
Artandi et al. [26] demonstrated that mTERT transgenic
FVB mice displayed a statistically significant susceptibility
to breast cancer. This murine strain is susceptible to
develop a variety of tumors such as lung adenocarcino-
mas, lymphomas, and sarcomas but is resistant to devel-
oping spontaneous breast carcinomas. The mTERT
transgenic FVB murine mammary tumors exhibited
diverse histological patterns. Additionally, preinvasive
lesions were noted in anatomically separate regions of the
mammary gland, suggesting that constitutive mTERT
expression led to the promotion of preneoplastic lesions.
The authors concluded that telomerase may have dual
roles of stabilizing telomeres and have a second role that
does not depend on the setting of limited telomere
reserve. Mad 2 is expressed at aberrantly high levels
throughout the cell cycle in cells with Rb pathway defects.
Hernando et al. [27] demonstrated that partial suppres-
sion of Mad2 expression to nearly normal levels in
immortalized cells resulted in a reduced aneuploid frac-
tion. The authors suggest that aberrant expression of
Mad2 results in a hyperactive spindle checkpoint, altering
the sequence of mitotic events and the fidelity of chromo-
some transmission. hTERT immortalized HMEC 4 dem-
onstrated consistent gain of chromosomes 5, 20, 1q, and
8q. c-Myc, which is located on 8q24, is a potential candi-
date gene for copy number increase in these cells.
Based on the keratin distribution in the normal mammary
gland [28], the epithelial tumor generated in this study
represents a poorly differentiated malignancy derived
from a lobular, luminal cell. This phenotype most likely
appears after selection in soft agar as the preceding cells
do express luminal markers. The epithelial tumor strongly
expresses cytokeratin 7, which is found predominantly in
luminal cells. It is negative for cytokeratin 20, consistent
with its mammary origins. It is also negative for cytokerat-
ins 8 and 18, which are found predominantly in the duc-
tal cells. It completely lacks cytokeratin 5, smooth muscle
myosin heavy chain, and calponin, which excludes deriva-
tion from the basal and myoepithelial compartments.
Finally, the tumor is negative for Estrogen receptor, Pro-
gesterone receptor, brst-2 antigen, and mammoglobin.
Brst-2 antigen is found predominantly in mammary
tumors with elements of apocrine differentiation while
mammoglobin is found in a minority of mammary
tumors [29].
The tumor is negative for E-cadherin staining, further rein-
forcing its putative lobular origin. Acs et al. [30] reviewed
the E-cadherin expression in 183 invasive mammary car-
cinomas and 198 carcinomas in situ and found that mod-
Western blotting (confirmed from three separate experi- ments) of human mammary epithelial cells (HMEC) from  donor 4 at various stages from mortal, early passage to the  epithelial tumor are shown below Figure 2
Western blotting (confirmed from three separate experi-
ments) of human mammary epithelial cells (HMEC) from 
donor 4 at various stages from mortal, early passage to the 
epithelial tumor are shown below. Volume intensity of H-ras 
is displayed on the bar graph at the top, and H-ras overex-
pression compared to the baseline mortal state is indicated 
below each bar. Lanes (from right to left): 1. HMEC from 
donor 4- post stasis, pre agonescence, passage 9. 2. RAO-1 
cells. 3. RAO-2 cells. 4. Cells from soft agar colony that 
developed into the epithelial tumor in nude mice. 5. RAO-4 
cells, cultured in monolayerCancer Cell International 2006, 6:15 http://www.cancerci.com/content/6/1/15
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erate to strong staining was present in all invasive and in
situ ductal carcinomas while virtually all in situ and inva-
sive lobular carcinomas lost expression of E-cadherin.
Droufakou et al. [31] analyzed 22 invasive lobular carci-
nomas and demonstrated several different mechanisms
for loss of E-cadherin expression including promoter
methylation, mutation, or loss of heterozygosity in any
combination. Methylation may also play a key role in
silencing E-cadherin expression in the tumor generated in
this study. As noted previously, the HMEC in this study
were transduced with mutant H-ras, cloned in soft agar,
and injected into nude mice. During this process, c-Myc
expression was reduced after passaging and transduction,
but apparently regained during soft agar cloning. The re-
expression of myc may be critical to the transformation of
HMEC. The oncogenic potency of the myc/ras combina-
tion has been known for quite some time [32]. The levels
of c-Myc and p53 rise with repeated passaging [11,33] in
hTERT immortalized HMEC. However, they are reduced
quite dramatically following H-ras61L transduction.
Because c-myc expression is detected in the soft agar col-
ony that gave rise to the epithelial tumor, as well as in the
tumor itself, we hypothesize that c-myc expression plays
an important role in mammary cell transformation. The
levels of p53 are reduced after Hras61L transduction, and
remain reduced which suggested that p53 is non-func-
tional in the epithelial tumors, as demonstrated by
absence of doxorubicin-induced G1 arrest.
Our summary of karyotypic changes involved in mam-
mary cell transformation is outlined in Figure 6. Normal
HMEC were allowed to passage through stasis, during
which time the p16 promoter was likely to have been epi-
genetically silenced. They were then immortalized with
hTERT. Cells first acquire the +der(1)t(1;8)(p13;q13), tri-
somy 5, trisomy 20. Following this, a fraction of the cells
undergo further rearrangement involving chromosome 1,
resulting in two related cell populations, one with translo-
cation of unidentified material to the long arm of chro-
mosome 1 at band 1q21 and the other with a
pseudoisodicentric chromosome 1 (Figure 6). We hypoth-
esize that these cell lines demonstrating the add(1) and
psu idic(1) represent the primary karyotypes of the mam-
mary carcinoma. Further complex karyotypic evolution
occurs beyond these cell lines populations.
Other in vitro transformation models include the Wein-
berg model [9], the Reddel model [11], and the Miller
model [34]. The tumors generated in the Weinberg study
were epithelial based on the pan-cytokeratin staining.
Toouli et al. [11] did not discuss the morphology of the
tumor generated in their study; however, it was presuma-
bly epithelial. To achieve mammary cell transformation,
the Weinberg laboratory [9,35] used a combination of
four genes (H-rasV12G (12×), hTERT, small t antigen, and
large T antigen), and the Reddel lab, the two viral onco-
genes (small t antigen, large T antigen) alone. In the Red-
del study, prolonged passaging of HMEC in vitro
produced malignancy, in contrast to a series of transduc-
tions. In our study, passaged immortal HMEC accumu-
lated some cytogenetic abnormalities but did not acquire
tumorigenicity. Transformation of immortal HMEC was
only associated with late-passage transduction of H-ras.
Elenbaas et al. [9] state a seven-fold excess of Ras was usu-
Flow cytometry data is represented below Figure 3
Flow cytometry data is represented below. There is no tetraploid population noted.Cancer Cell International 2006, 6:15 http://www.cancerci.com/content/6/1/15
Page 8 of 11
(page number not for citation purposes)
ally inadequate to transform their HMEC, and that it was
only with twelve fold excess that transformation occurred
regularly. Our study suggests that a five-fold excess of 61L
mutant H-ras is sufficient for transformation. Although
high levels of H-ras were associated with transformation
of HMEC in the Weinberg study, other genetic changes are
required as well. Only 52% of mice in the Weinberg mam-
mary epithelial cell study developed tumors with an aver-
age latency of 52 days. This is in contrast to Weinberg's
earlier results [10] in which transformed human embry-
onic kidney cells and human fibroblasts produced tumors
in nude mice in 21 days. These mesenchymal tumors
showed virtually no cytogenetic changes, suggesting a less
complex etiology. Perhaps connective tissue is endowed
with all the tools needed for successful tumor invasion,
while epithelium must recruit surrounding stromal cells
early on. One of the tumors in the Reddel study required
68 days to develop, while the other malignant line grew in
21 days. H-ras transduction was not employed. The Miller
model, developed at Wayne State University, is unique
because of its ability to generate premalignant breast
lesions. MCF 10A cells were transfected with H-ras V12G
to generate MCF10AT, which were passaged by serial
xenograft transplantations. Injection of cells into nude-
(a) Primary HMEC and RAO-4 cells were treated with FTI-277, a potent farnesyl transferase inhibitor, and effects were  observed Figure 4
(a) Primary HMEC and RAO-4 cells were treated with FTI-277, a potent farnesyl transferase inhibitor, and effects were 
observed. The membranous ruffles of cells showed a significant flattened morphological appearance after treatment with FTI-
277 at 2.5 and 5.0 μM concentrations. Although cellular morphological changes were not observed in primary HMEC at these 
concentrations, we observed some cell death with FTI-277 treatment at 2.5 and 5.0 μM concentrations. (b) We found a reduc-
tion in RAO-4 cell proliferation with FTI-277 treatment at 5.0 μM concentrations. The black bars represent untreated epithe-
lial tumor cells while the white bars represents treated epithelial tumor cells.Cancer Cell International 2006, 6:15 http://www.cancerci.com/content/6/1/15
Page 9 of 11
(page number not for citation purposes)
beige mice resulted in heterogenous histologies, including
hyperplastic lesions, ductal carcinoma in situ, and squa-
mous cell carcinoma [36]. The karyotype of MCF 10AT
was very stable, with a few cytogenetic alterations occur-
ring with progression [37]. Further xenograft passaging of
MCF10AT led to the development of MCF10ACA1, which
rapidly and directly formed large tumors without a pre-
malignant phase [38]. The HMEC in our study may have
been nearly or fully transformed prior to injection, as
tumors rapidly formed tumors in 21 days in 100% of
injected mice. The non-functionality of p53 in both the
Weinberg and Reddel tumors might be due to the pres-
ence of SV40 large T antigen. The tumors studied by Miller
were p53 positive, and some were estrogen receptor posi-
(a) A representative G-banded karyotype of the mammary epithelial tumor is seen below Figure 5
(a) A representative G-banded karyotype of the mammary epithelial tumor is seen below. The mainline karyotype is 
49,XX,+der(1)t(1;8)(p13;q13),psu idic (1)(q23),+5,+20. (b) Spectral Karyotype of the cells from the mammary epithelial tumor 
confirms the G-banded cytogenetic analysis.Cancer Cell International 2006, 6:15 http://www.cancerci.com/content/6/1/15
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tive. Although no exogenous viral oncogenes were intro-
duced into our transformed cells, p53 appears to be non-
functional, based on the doxorubicin G1 arrest assay. The
loss of functional p53 may promote genetic instability in
the mammary cells, allowing the acquisition of the com-
plex changes required for transformation.
Conclusion
The combination of cytogenetic changes along with H-ras
61L overexpression led to transformation in a donor's
cells hTERT immortalized HMEC and allowed us to out-
line a stepwise model to transformation. These cytoge-
netic changes, which give us clues as to the nature of the
genetic changes taking place, reflect a portion of the
molecular events that are proceeding in our model of
mammary transformation. Other molecular events
required for transformation are likely taking place
through alternate means such as epigenetic changes or
altered translational regulation.
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